A Study Assessing the Safety and Tolerability of LY03020 in Chinese Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 19, 2024

Primary Completion Date

February 13, 2025

Study Completion Date

February 13, 2025

Conditions

SchizophreniaAlzheimer's Disease Psychosis

Interventions

DRUG

LY03020

LY03020 for one single dose

DRUG

Placebo

Placebo for one single dose

Trial Locations (1)

Beijing AnDing Hospital Capital Medical University, Beijing

All Listed Sponsors

lead

Luye Pharma Group Ltd.

INDUSTRY

NCT06556966 - A Study Assessing the Safety and Tolerability of LY03020 in Chinese Healthy Subjects | Biotech Hunter | Biotech Hunter